Accès à distance ? S'identifier sur le proxy UCLouvain
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
Primary tabs
- Open access
- 414.09 K
Document type | Article de périodique (Journal article) – Article de recherche |
---|---|
Access type | Accès libre |
Publication date | 2011 |
Language | Anglais |
Journal information | "The Lancet Neurology" - Vol. 10, no. 8, p. 745-758 (2011) |
Peer reviewed | yes |
Publisher | TheLancet Publishing Group ((United Kingdom) London) |
issn | 1474-4422 |
e-issn | 1474-4465 |
Publication status | Publié |
Affiliations |
UCL
- SSS/IONS/CEMO - Pôle Cellulaire et moléculaire UCL - (SLuc) Service de neurologie |
MESH Subject | Animals ; Practice Guidelines as Topic ; Treatment Outcome ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Drug Monitoring ; Humans ; Integrin alpha4beta1 ; Leukoencephalopathy, Progressive Multifocal ; Multiple Sclerosis, Relapsing-Remitting ; Patient Selection |
Links |
Bibliographic reference | Kappos, Ludwig ; Bates, David ; Edan, Gilles ; Eraksoy, Mefkûre ; Garcia-Merino, Antonio ; et. al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.. In: The Lancet Neurology, Vol. 10, no. 8, p. 745-758 (2011) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/124907 |